The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The company has reported total income of Rs.826.40 crores for FY 2020-21
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
The company has posted net loss of Rs. 99.54 crores for the period ended March 31, 2020
Subscribe To Our Newsletter & Stay Updated
